“Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s108, https://doi.org/10.25251/skin.4.supp.108.